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Aim of the study: To present a case of
a patient with cervical carcinoma in stage
IIA who was diagnosed with pelvic bone
sarcoma 28 years after radiotherapy.
Case presentation: A 37-year-old woman
with IIA cervix cancer was treated with
external beam irradiation and bra -
chytherapy. The patient had undergone
conventionally fractionated external
beam irradiation using the “box” tech-
nique, with the total dose of 50 Gy and
brachytherapy with radium applicators
(intrauterine tube and fornix applicator)
with the dose of 60 Gy calculated at
point A. After treatment she was followed
up for 2 years. Twenty-six years later, 
inoperable pelvic bone sarcoma was
diagnosed within the irradiated field. The
clinical course was aggressive and rapid
progression during chemotherapy was
observed.
Conclusions: For patients receiving ra-
diotherapy, long-term careful follow-
up is mandatory due to second cancer
risk. In the case of any suspicious symp-
toms, such patients need proper diag-
nosis to detect any disease as early as
possible.
Key words: cervix cancer, radiotherapy,
pelvic bones, radiation-induced sarcoma.
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Introduction
An increasing number of women survive after cervical carcinoma treatment
and live longer than 5-10 years without signs of recurrence. Some of these sur-
vivors may develop a second cancer caused by primary anticancer treatment.
Aging is the most important factor of second cancer risk in cured cancer patients.
Post-irradiation tumours can occur even 60 years after radiotherapy. Both
chemotherapy and radiotherapy increase the risk of second cancer [1]. Epi-
demiological data concerning irradiation-induced sarcoma risk showed an av-
erage relative risk of 1.42 at 1 Sv (unit of dose equivalent, for gamma irradiation
1 Sv = 1 Gy) [2]. Incidence of radiation-induced tumours ranges from 0.5% to 1.6%.
We present a case of radiation-associated sarcoma of pelvic bone following ra-
diotherapy for cervical carcinoma. The diagnostic and therapeutic dilemmas and
mechanisms of development of irradiation-induced sarcoma are discussed.
Case description
A 37-year-old Polish woman was referred to the Institute of Oncology in
Krakow in July of 1980 with diagnosis of squamous cell cervical carcinoma in
FIGO stage IIA. Between 31 July and 2 September 1980, the patient underwent
conventionally fractionated external beam irradiation with the total dose of 
50 Gy and brachytherapy with radium applicators (intrauterine tube and fornix
applicators) with the dose of 60 Gy calculated at point A. The patient was fol-
lowed without signs of recurrence until March 1982. She was again referred
to our hospital in May of 2008, 28 years after radiotherapy. For five months,
the patient had been suffering from pain spreading from the back to the right
sacroiliac joint. On gynaecological examination no signs of cervix cancer re-
currence were found. X-ray of the pelvic bones showed an osteolytic focus of
about 5 cm × 8 cm, in the right iliac ala at the level of the right sacroiliac joint.
A computed tomography (CT) scan confirmed the presence of inoperable os-
teolytic destruction in the right iliac ala along the sacroiliac joint, with pene-
tration into the articular space and inflammatory reaction in surrounding soft
tissues. The imaging results were returned to the patient, so the present pa-
per does not contain any photographic documentation of the examinations
performed. Ultrasound controlled core-needle biopsy revealed malignant spin-
dle cell neoplasm forming either long and storiform fascicles or haeman-
giopericytoma-like texture (Fig. 1). The tumour cells were characterized by nu-
merous pleomorphic cells and significant mitotic activity [up to 2-3 mitotic figures
in one high power field (HPF)] (Fig. 2). The tumour cells dyed positively with
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antibodies against vimentin (strong diffuse cytoplasmic 
reaction), CD68 and desmin (positive reaction in single
cells) (Fig. 2. Insert). The immunohistochemical staining for
broad spectrum of cytokeratins (AE1/AE3, CK7, CK5/6,
CAM5.2) gave negative results.
The histological and immunohistochemical picture of the
tumour was consistent with high grade pleomorphic
leiomyosarcoma.
Three courses of chemotherapy with Adriamycin were giv-
en. Due to evidence of progression observed on X-ray and
CT scan and rapid worsening of general status, chemother-
apy was discontinued in October 2008.
The patient received symptomatic treatment prescribed by
a general practitioner and later was lost from the follow-up.
Discussion
The criteria describing post-irradiation nature of second
malignancy include second malignancy arising within the ir-
radiation field, tumour histology other than primary, and a la-
tent period of 5 years minimum [3]. The present case fits the
above criteria, so finally a diagnosis of irradiation-induced 
sarcoma was made.
The risk of second malignancy within the irradiated area
in patients with cervical carcinoma treated with irradiation
has been assessed in large epidemiological studies presented
by Boice et al. [4] and Kleinerman et al. [5]. Both authors not-
ed increased incidence of rectal, bladder, vaginal and ovari-
an carcinoma, soft tissue sarcoma and leukaemia. Consistently
increasing risk particularly concerns organs receiving a dose
higher than 1 Gy, rising from 10% in the first decade after ir-
radiation to about 50% after 30 or more years. The risk is high-
est when irradiation therapy was given at a young age [6-10].
The threshold dose for radiation-induced tumours is not
known. A lot of authors have noted increased incidence of
soft tissue and bone sarcoma [11-16]. Kleinerman et al. [5] found
that relative risk for bone sarcoma in the irradiated field was
3.0. The overall incidence of post-irradiation sarcoma ranged
from 0.03% after 10 years to 0.8% after 30 years [15, 17-19].
The most common types of radiation-induced sarcomas
are osteosarcoma, fibrosarcoma, malignant fibrous histio-
cytoma, and angiosarcoma [9, 20-22]. High grade pleomor-
phic leiomyosarcoma has been reported rarely [21, 23]. La-
grange et al. [21] in a retrospective analysis of 80 cases of
post-irradiation sarcoma noted 3 cases with soft tissue
leiomyosarcoma and one with bone leiomyosarcoma. Kacz-
marek-Borowska et al. [23] noted one case with abdominal
wall leiomyosarcoma that developed 11 years after cervical
carcinoma irradiation. Olcina et al. [24] described one case
of radiation-induced leiomyosarcoma after breast carcino-
ma treatment. Brockstein et al. [25] noted 3 cases of
leiomyosarcoma occurring 9-27 years after radiation and
chemotherapy. Brockstein et al. [25] were able to find in the
English language literature 33 cases (mostly as single case
reports) of radiation-induced leiomyosarcoma, which de-
veloped 6-35 years after radiation therapy.
Radical resection remains the main method of treatment
in radiation-induced sarcomas, but resectability depends on
site (bone or soft tissue) and size of tumour. Operability rate
ranged from 49% to 74% [16, 20, 26]. Management of these
Fig. 1. Malignant spindle cell neoplasm forming either long and
storiform fascicles or haemangiopericytoma-like texture
Fig. 2. The tumour cells are characterized by numerous pleomor-
phic cells and significant mitotic activity (up to 2-3 mitotic figu-
res in one HPF) (Fig. 2). The tumour cells dyed positively with
antibodies against vimentin (strong diffuse cytoplasmic reaction),
CD68 and desmin (positive reaction in single cells) (Fig. 2. Insert)
tumours must take into consideration the possibility of com-
plete resection and the impact of surgery on quality of life.
In the present case, an inoperable sarcoma was located in
the pelvic bones. The clinical course was aggressive, with rapid
progression during chemotherapy.
The median survival reported by Brady et al. [13] was one
year, and the 5-year survival was 17% for patients with a tu-
mour of more than 5 cm in diameter and not completely re-
sected. Bjerkehagen et al. [27] noted 33% 5-year crude sur-
vival. Inoue [18] noted 5-year overall survival for patients with
resectable lesion of the extremities at the level of 68.2% com-
pared with 27.3% for those with central type (pelvis,
head/neck, spine, scapula). Similar results were also achieved
in other reports [28, 29]. The poor survival rate is the result
of significant delay in diagnosis, large, unresectable and ag-
gressive tumours, and lack of effective methods of treatment
apart from radical surgery.
Chemotherapy and re-irradiation have very limited ap-
plication, mainly as palliative treatment [26, 29]. Paclitaxel
and anti-angiogenic drugs, such as sorafenib and sunitinib,
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have shown some efficiency in angiosarcomas [30].
Chemotherapy can be administered in the neoadjuvant pat-
tern, before surgical resection, to improve local control and
eradicate subclinical metastatic disease. Guetz et al. [31] 
noted clinical partial remission in 9 out of 19 patients (47%)
receiving neoadjuvant chemotherapy (doxorubicin + ifos-
famide + dacarbazine). Eight of them were operated on. Patho-
logical analysis showed two cases of complete histological
response. Re-irradiation can be relatively safe and effective
in selected patients, but there are concerns about serious se-
quelae. Furthermore, repeated high-dose radiotherapy is of-
ten impossible due to limited bone marrow function [32, 33].
De Jong [34] indicated re-irradiation plus hyperthermia as
a feasible method in patients with post-irradiation sarcoma.
There are several theories describing mechanisms of de-
velopment of irradiation-induced tumours. Guerrero et al. [35]
suggested that critical cellular molecules are directly ionized,
or irradiation indirectly acts through mediators such oxygen
free radicals and finally DNA injury results in induction of a so-
matic mutation and activation of proto-oncogene K-ras. Ex-
perimental evidence showed p53 gene alterations or increased
p53 messenger ribonucleic acid (mRNA) levels in post-irra-
diation murine sarcomas. The retinoblastoma gen (Rb) mu-
tations also have been detected [36]. Little [37] described ev-
idence indicating that not only activation of oncogenes,
tumour suppressor genes and the loss of cell-cycle check-
points within irradiated cells are important. Genetic conse-
quences of irradiation may occur in the neighbouring cells
by gap junction mediated cell-cell communication and ac-
tivation of the p53 damage response pathway. In Trott’s [38]
opinion, second cancers in high dose volumes are caused by
the promoting effects of chronic radiation damage: atrophy
and persistent inflammation. Holt [39] suggested a two-mu-
tation model of carcinogenesis, which fitted the influence
of low dose irradiation: a specific mutation in a stem cell in-
creases its rate of proliferation and pre-malignant cells will
develop. A second specific mutation in any one of these will
make it malignant. Modern radiation techniques such as in-
tensity-modulated radiotherapy (IMRT) might increase the
risk of radiation-induced sarcomas. The move from con-
ventional to three-dimensional conformal radiotherapy was
implicated in reduction of the normal tissue volume receiving
a high dose and an increase in dose to the tumour and a lim-
ited part of normal tissue. This may correlate with a decrease
in the number of induced sarcomas. However, the move to
IMRT involves more fields, and a larger volume of normal tis-
sue receives lower doses while the total body exposure is
increased. Both factors may cause greater risk of radiation-
induced tumours [19, 38, 40, 41]. Genetic predisposition and
other risk factors such tobacco, alcohol, hormonal disturbance
and diet also play an important role. The increased risk of
second cancers is well documented in patients with hered-
itary form of retinoblastoma [42]. In members of families with
Li-Fraumeni syndrome, germline mutations in tumour sup-
pressor genes may increase the risk of second cancer [43].
The risk of radiation-induced sarcoma is relatively small
compared with the benefits of radical or adjuvant radiotherapy.
Careful follow-up after effective radiotherapy should be con-
tinued for many years: early diagnosis of second cancer may
help in more effective treatment of these tumours.
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